Innate Pharma (IPHYF) Cash from Financing Activities (2019 - 2024)
Historic Cash from Financing Activities for Innate Pharma (IPHYF) over the last 6 years, with Q4 2024 value amounting to -$6.4 million.
- Innate Pharma's Cash from Financing Activities fell 20350.91% to -$6.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$9.9 million, marking a year-over-year decrease of 5550.17%. This contributed to the annual value of -$6.4 million for FY2024, which is 20350.91% down from last year.
- Innate Pharma's Cash from Financing Activities amounted to -$6.4 million in Q4 2024, which was down 20350.91% from -$2.1 million recorded in Q4 2023.
- Over the past 5 years, Innate Pharma's Cash from Financing Activities peaked at -$1.0 million during Q2 2022, and registered a low of -$6.4 million during Q4 2024.
- Moreover, its 5-year median value for Cash from Financing Activities was -$1.4 million (2021), whereas its average is -$2.1 million.
- Per our database at Business Quant, Innate Pharma's Cash from Financing Activities soared by 3061.85% in 2022 and then crashed by 20350.91% in 2024.
- Quarter analysis of 5 years shows Innate Pharma's Cash from Financing Activities stood at -$1.4 million in 2020, then fell by 5.21% to -$1.5 million in 2021, then fell by 26.32% to -$1.9 million in 2022, then decreased by 13.42% to -$2.1 million in 2023, then tumbled by 203.51% to -$6.4 million in 2024.
- Its Cash from Financing Activities was -$6.4 million in Q4 2024, compared to -$2.1 million in Q4 2023 and -$1.4 million in Q2 2023.